The Hemophilia Therapeutics Market is forecasted to become a $10 billion market by 2017
The global hemophilia therapeutics market for 2009 was valued at $6.5 billion. Baxter International, Bayer Healthcare, CSL Behring, Pfizer, Novo Nordisk, Grifols (Talecris Biotherapeutics), Octapharma AG are the key players operating in the market. The key brands of the market include NovoSeven, Advate, BeneFIX, XYNTHA, FEIBA VH, Helixate FS, Kogenate FS and others. The market is estimated to reach $10.4 billion through 2017. At present, some of key first in class drugs are in Phase II, these include ARC19499, Ataluren (PTC124) and Rituximab. More importantly several new first in class drugs are currently in the discovery and preclinical phase. A key development in the hemophilia therapeutics market has been that Grifols agreed to purchase Talecris Biotherapeutics for $3billion. This deal was initiated in June 2010 and has the potential to bring the company’s value at par with Baxter International in the blood-based infusions market. The Annual Global Survey 2008, World Federation of Hemophilia reveals that over 12,000 cases of hemophilia A and nearly 4,000 cases of hemophilia B were diagnosed in the US, followed by UK with nearly 5,000 cases of hemophilia A and over 1,000 cases of hemophilia B.
Current Treatment Options Meet the Market Demand
The current market is served by NovoSeven, Advate, BeneFIX, XYNTHA, FEIBA VH, Helixate FS, Kogenate FS and others. Baxter International, Bayer Healthcare, CSL Behring, Pfizer, Novo Nordisk, Grifols (Talecris Biotherapeutics), Octapharma AG have significant presence in hemophilia therapeutics market. The market currently offers clotting factor enhancers and coagulation factor substitute drugs, moreover 51 drugs are in various phases of clinical development. Currently several drugs are at the discovery and preclincial stage.
Population Growth, Shift in Treatment Regimes from Episode Based Treatment to Prophylactic Treatment are the Major Drivers for the Market
Rising population acts as a major driver to the hemophilia therapeutics market. More importantly, the elderly population is at a relatively higher risk to get affected by hemophilia. Increasing awareness among the population has initiated the need for prophylactic treatment of hemophilia. Moreover, pharmaceutical companies are investing in research and development in an attempt to bring about advancement in the prophylactic treatment for hemophilia. Availability of advanced and convenient delivery systems has increased patient compliance. Therefore all these factors have acted as drivers for the hemophilia therapeutics market.
Treatment Affordability and Diagnosis Rate of the Disease are the Major Barriers for the Market
At present the treatment options available for hemophilia are high priced. This acts as a major barrier for the hemophilia therapeutics market. Factor concentrates and recombinant coagulation factors are widely used to treat hemophilia, these products are available at high prices. This has led to a negative effect on the market. Similarly, low rate of diagnosis also act as barrier to the hemophilia therapeutics market. Currently, several patients suffering from hemophilia remain undiagnosed for longer period of time.
Strong Pipeline Candidates are expected to Intensify Future Competition
The pipeline for hemophilia therapeutics market is strong, with 51 molecules being evaluated for treating hemophilia. At present, the pipeline consists of 13 first in class drugs at different phases of clinical trials. Of the total, more than 50% of the pipeline drugs are currently in the discovery and preclinical stage. Several of these drugs in the hemophilia therapeutics pipeline are classified as me too drugs.
Future Market Implications
Novo Nordisk, Baxter International, Ipsen / Inspiration Biopharmaceuticals, Bayer Healthcare, CSL Behring, GTC Biotherapeutics, Fresenius Kabi, Octapharma AG, Pfizer are the few companies developing new drugs for hemophilia. A total of 51 drugs are currently under development. These drugs would offer a wide range of options for treatment of hemophilia.
For further details, visit: www.globaldata.com/reportstore
Or please add this link to your browser.
http://www.globaldata.com/reportstore/Report.aspx?ID=Hemophilia-Pipeline-Assessm
The Hemophilia Therapeutics Market is forecasted to become a $10 billion market by 2017
The global hemophilia therapeutics market for 2009 was valued at $6.5 billion. Baxter International, Bayer Healthcare, CSL Behring, Pfizer, Novo Nordisk, Grifols (Talecris Biotherapeutics), Octapharma AG are the key players operating in the market. The key brands of the market include NovoSeven, Advate, BeneFIX, XYNTHA, FEIBA VH, Helixate FS, Kogenate FS and others. The market is estimated to reach $10.4 billion through 2017. At present, some of key first in class drugs are in Phase II, these include ARC19499, Ataluren (PTC124) and Rituximab. More importantly several new first in class drugs are currently in the discovery and preclinical phase. A key development in the hemophilia therapeutics market has been that Grifols agreed to purchase Talecris Biotherapeutics for $3billion. This deal was initiated in June 2010 and has the potential to bring the company’s value at par with Baxter International in the blood-based infusions market. The Annual Global Survey 2008, World Federation of Hemophilia reveals that over 12,000 cases of hemophilia A and nearly 4,000 cases of hemophilia B were diagnosed in the US, followed by UK with nearly 5,000 cases of hemophilia A and over 1,000 cases of hemophilia B.
Current Treatment Options Meet the Market Demand
The current market is served by NovoSeven, Advate, BeneFIX, XYNTHA, FEIBA VH, Helixate FS, Kogenate FS and others. Baxter International, Bayer Healthcare, CSL Behring, Pfizer, Novo Nordisk, Grifols (Talecris Biotherapeutics), Octapharma AG have significant presence in hemophilia therapeutics market. The market currently offers clotting factor enhancers and coagulation factor substitute drugs, moreover 51 drugs are in various phases of clinical development. Currently several drugs are at the discovery and preclincial stage.
Population Growth, Shift in Treatment Regimes from Episode Based Treatment to Prophylactic Treatment are the Major Drivers for the Market
Rising population acts as a major driver to the hemophilia therapeutics market. More importantly, the elderly population is at a relatively higher risk to get affected by hemophilia. Increasing awareness among the population has initiated the need for prophylactic treatment of hemophilia. Moreover, pharmaceutical companies are investing in research and development in an attempt to bring about advancement in the prophylactic treatment for hemophilia. Availability of advanced and convenient delivery systems has increased patient compliance. Therefore all these factors have acted as drivers for the hemophilia therapeutics market.
Treatment Affordability and Diagnosis Rate of the Disease are the Major Barriers for the Market
At present the treatment options available for hemophilia are high priced. This acts as a major barrier for the hemophilia therapeutics market. Factor concentrates and recombinant coagulation factors are widely used to treat hemophilia, these products are available at high prices. This has led to a negative effect on the market. Similarly, low rate of diagnosis also act as barrier to the hemophilia therapeutics market. Currently, several patients suffering from hemophilia remain undiagnosed for longer period of time.
Strong Pipeline Candidates are expected to Intensify Future Competition
The pipeline for hemophilia therapeutics market is strong, with 51 molecules being evaluated for treating hemophilia. At present, the pipeline consists of 13 first in class drugs at different phases of clinical trials. Of the total, more than 50% of the pipeline drugs are currently in the discovery and preclinical stage. Several of these drugs in the hemophilia therapeutics pipeline are classified as me too drugs.
Future Market Implications
Novo Nordisk, Baxter International, Ipsen / Inspiration Biopharmaceuticals, Bayer Healthcare, CSL Behring, GTC Biotherapeutics, Fresenius Kabi, Octapharma AG, Pfizer are the few companies developing new drugs for hemophilia. A total of 51 drugs are currently under development. These drugs would offer a wide range of options for treatment of hemophilia.
For further details, visit: www.globaldata.com/reportstore
Or please add this link to your browser.
http://www.globaldata.com/reportstore/Report.aspx?ID=Hemophilia-Pipeline-Assessm